Kubota et al.
J ) 1.8 and 1.3 Hz), 6.47 (1H, d, J ) 1.8 Hz), 8.02 (1H, s), 8.48
(1H, br), 8.77 (1H, s); 13C NMR (CDCl3) δ -5.42, -5.39, -4.6,
18.0, 18.3, 25.7, 25.8, 27.4, 40.4, 58.5, 80.2, 92.1, 99.9, 122.8,
139.9, 149.5, 151.4, 152.4, 161.8, 175.7; FAB-MS (m/z) 562 (M+
+ H). Anal. Calcd for C27H47N5O4Si2: C, 57.72; H, 8.43; N, 12.46.
Found: C, 57.70; H, 8.61; N, 12.47.
structure, were efficiently prepared by oxidation with DMDO.
Stereoselectivity of epoxide ring opening with Me3Al, anti
versus syn, was investigated by changing the amount of Me3-
Al, the solvent, the O-silyl protecting group, and the reaction
temperature. Reaction of the 3′,5′-bis-O-TBDMS epoxide 9
carried out in CH2Cl2 in a range of 0 to -80 °C uniformly
resulted in the preferential formation of the anti-ring-opened
product 12, which is in sharp contrast to the reported stereo-
selectivity for epoxides derived from 3,4-dihydro-2H-pyran and
glycal derivatives.
The fact that 14 lacking the adenine base, upon reacting in
CH2Cl2 at -30 °C, gave solely the syn-opened product 15
suggests an important role of the nucleobase for the observed
anti-selectivity. By employing 9, it was also possible to change
stereochemical bias toward exclusive formation of the syn-
opened product 13, simply by carrying out the reaction in an
ethereal solvent, such as THF, Et2O, and 1,4-dioxane. These
results led us to propose a reaction mechanism depicted in
Scheme 4. Based on this mechanism, the highest anti-selectivity
(anti/syn ) 50/1) was accomplished by reacting the 2′-O-SiEt3
epoxide 10 in CH2Cl2 at -80 °C.
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-4-(3-chlorobenzoyloxy)-
â-D-xylofuranosyl]-N6-pivaloyladenine (8). To a CH2Cl2 (5 mL)
solution of 5 (200 mg, 0.36 mmol) was added a CH2Cl2 (20 mL)
solution of m-CPBA (purity minimum 65%, 280 mg, 1.07 mmol).
After being stirred for 1.5 h at room temperature, the reaction
mixture was treated with Et3N (0.15 mL) and partitioned between
CH2Cl2 and H2O. Evaporation of the organic layer followed by
column chromatography (hexane/EtOAc ) 2/1) gave 8 (foam, 42.9
mg, 16%): UV (MeOH) λmax 272 nm (ꢀ 21 200), λmin 248 nm (ꢀ
1
12 800); H NMR (CDCl3) -0.14, -0.02, 0.05, and 0.07 (12H,
each as s), 0.72 and 0.86 (18H, each as s), 1.42 (9H, s), 4.34 and
4.38 (2H, each as d, J ) 11.1 Hz), 4.69 (1H, dd, J ) 3.1 and 7.3
Hz), 4.73 (1H, dd, J ) 3.1 and 3.8 Hz), 5.59 (1H, d, J ) 7.3 Hz),
6.25 (1H, d, J ) 3.8 Hz), 7.38-7.42, 7.55-7.58, 7.94-7.96, and
8.03-8.04 (4H, m), 8.23 (1H, s), 8.59 (1H, br), 8.77 (1H, s); 13C
NMR (CDCl3) δ -5.4, -5.1, -4.8, 17.8, 18.4, 25.5, 25.9, 27.5,
40.7, 62.0, 80.4, 81.9, 91.2, 112.6, 123.5, 128.1, 129.8, 129.9, 131.9,
133.5, 134.6, 142.2, 150.2, 150.7, 152.6, 163.9, 175.7; FAB-MS
(m/z) 734 (M+ + H). Anal. Calcd for C34H52ClN5O7Si2: C, 55.60;
H, 7.14; N, 9.54. Found: C, 55.55; H, 7.25; N, 9.46.
Since 9-(â-D-xylofuranosyl)adenine has long been known as
a biologically active nucleoside analogue23 and since nucleosides
having a carbon substituent at the 4′-position constitute a
promising class of antiviral agents,24,25 we believe that the
present study may be useful for the development of new
biologically active nucleoside analogues.
The Epoxide 9 Formed by DMDO Oxidation of 5. This
compound was not fully characterized due to its instability. Spectral
data of this compound are as follows: 1H NMR (CDCl3) δ 0.09,
0.11, and 0.13 (12H, each as s), 0.92 (18H, s), 1.41 (9H, s), 3.72
(1H, s), 4.17 and 4.27 (2H, each as d, J ) 12.3 Hz), 4.63 (1H, s),
6.54 (1H, s), 8.38 (1H, s), 8.56 (1H, br), 8.73 (1H, s); FAB-MS
(m/z) 578 (M+ + H).
Experimental Section
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-3-deoxy-â-D-glycero-
pent-3-enofuranosyl]adenine (2). To a pyridine (20 mL) solution
of 1 (2.0 g, 8.06 mmol) was added TBDMSCl (3.6 g, 24.2 mmol)
at 0 °C. The mixture was stirred at 0 °C for 5 min and then at
room temperature for 24 h. The reaction mixture was partitioned
between CH2Cl2 and saturated aq NaHCO3. Evaporation of the
organic layer followed by column chromatography (CHCl3/MeOH
) 60/1) gave 2 (foam, 3.69 g, 96%): UV (MeOH) λmax 260 nm (ꢀ
Reaction of Me3Al with 9 Listed in Entry 4 of Table 1 as a
Typical Procedure: Formation of 9-[2,5-Bis-O-(tert-butyldim-
ethylsilyl)-4-C-methyl-â-D-xylofuranosyl]-N6-pivaloyladenine (12)
and 9-[2,5-Bis-O-(tert-butyldimethylsilyl)-4-C-methyl-R-L-ara-
binofuranosyl]-N6-pivaloyladenine (13). To a CH2Cl2 (12 mL)
solution of 5 (200 mg, 0.36 mmol) was added an acetone solution
of DMDO (ca. 0.04M, 13.2 mL, 0.53 mmol) under positive pressure
of dry Ar at -30 °C. After the mixture was stirred for 0.5 h at
-30 °C, the solution containing 9 was evaporated and dried under
diminished pressure. Compound 9 thus prepared was dissolved in
CH2Cl2 (12 mL) and cooled to -30 °C. To this was added Me3Al
(1.03 M hexane solution, 2.12 mL, 2.14 mmol). The reaction
mixture was stirred for 4.5 h at -30 °C, quenched by adding
saturated aq NH4Cl, and filtered through a Celite pad. The filtrate
was extracted with CH2Cl2. Column chromatography (hexane/
EtOAc ) 1/1) of the organic layer gave a mixture of 12 and 13
(foam, 190.1 mg, 90%, 12/13 ) 5/1). HPLC (hexane/EtOAc )
1/1) separation of the mixture gave analytical pure 12 (foam, tR
10.9 min) and 13 (foam, tR 13.0 min).
Physical date for 12: UV (MeOH) λmax 272 nm (ꢀ 18 100), λmin
235 nm (ꢀ 4 300); 1H NMR (CDCl3) δ -0.08, 0.04, 0.09, and 0.10
(12H, each as s), 0.85 and 0.92 (18H, each as s), 1.41 (9H, s), 1.43
(3H, s), 3.77 and 3.88 (2H, each as d, J ) 10.6 Hz), 4.04 (1H, d,
J ) 1.8 Hz), 4.60 (1H, dd, J ) 3.5 and 1.8 Hz), 4.93 (1H, br), 6.04
(1H, d, J ) 3.5 Hz), 8.29 (1H, s), 8.59 (1H, br), 8.76 (1H, s); 13C
NMR (CDCl3) δ -5.5, -5.3, -5.0, -4.8, 17.9, 18.3, 21.5, 25.6,
26.0, 27.5, 40.6, 67.3, 83.0, 84.3, 87.1, 90.2, 123.3, 142.2, 149.8,
151.1, 152.5, 175.7; FAB-MS (m/z) 594 (M+ + H). Anal. Calcd
for C28H51N5O5Si2: C, 56.63; H, 8.66; N, 11.79. Found: C, 56.53;
H, 8.84; N, 11.76.
1
15 200), λmin 231 nm (ꢀ 4 100); H NMR (CDCl3) δ 0.06, 0.09,
0.10, and 0.11 (12H, each as s), 0.89 and 0.92 (18H, each as s),
4.26 and 4.30 (2H, each as d, J ) 14.6 Hz), 5.18 (1H, d, J ) 1.3
Hz), 5.25 (1H, dd, J ) 1.8 and 1.3 Hz), 5.58 (2H, br), 6.41 (1H, d,
J ) 1.8 Hz), 7.85 (1H, s), 8.39 (1H, s); 13C NMR (CDCl3) δ -5.40,
-5.38, -4.54, -4.51, 18.1, 18.3, 25.7, 25.8, 58.6, 80.1, 91.9, 99.8,
119.5, 137.7, 149.7, 153.4, 155.4, 161.8; FAB-MS (m/z) 478 (M+
+ H). Anal. Calcd for C22H39N5O3Si2: C, 55.31; H, 8.23; N, 14.66.
Found: C, 55.27; H, 8.36; N, 14.62.
9-[2,5-Bis-O-(tert-butyldimethylsilyl)-3-deoxy-â-D-glycero-
pent-3-enofuransyl]-N6-pivaloyladenine (5). To a CH2Cl2 (20 mL)
solution of 2 (5.8 g, 12.1 mmol) was added i-Pr2NEt (3.2 mL, 18.2
mmol) and pivaloyl chloride (1.8 mL, 14.6 mmol) under positive
pressure of dry Ar at 0 °C. After being stirred for 2 h at 0 °C, the
reaction mixture was partitioned between CH2Cl2 and saturated aq
NaHCO3. Evaporation of the organic layer followed by column
chromatography (hexane/EtOAc ) 5/1) gave 5 (foam, 5.85 g,
86%): UV (MeOH) λmax 272 nm (ꢀ 17 800), λmin 236 nm (ꢀ 6 000);
1H NMR (CDCl3) δ 0.05, 0.08, 0.10, and 0.11 (12H, each as s),
0.89 and 0.92 (18H, each as s), 1.41 (9H, s), 4.26 and 4.31 (2H,
each as d, J ) 14.6 Hz), 5.17 (1H, d, J ) 1.3 Hz), 5.26 (1H, dd,
(23) For an example, see: Ellis, D. B.; LePage, G. A. Mol. Pharmacol.
1965, 1, 231.
(24) For an excellent review, see: Hayakawa, H.; Kohgo, S.; Kitano,
K.; Ashida, N.; Kodama, E.; Mitsuya, H.; Ohrui, H. AntiViral Chem.
Chemother. 2004, 15, 169.
(25) For a recent example, see: Tanaka, H.; Haraguchi, K.; Kumamoto,
H.; Baba, M.; Cheng, Y.-C. AntiViral Chem. Chemother. 2005, 16, 217.
Physical data for 13: UV (MeOH) λmax 272 nm (ꢀ 18 300),
λ
min 237 nm (ꢀ 6 300). 1H NMR (CDCl3) δ -0.04, 0.06, and 0.08
(12H, each as s), 0.87 and 0.92 (18H, each as s), 1.39 (3H, s), 1.41
(9H, s), 3.62 and 3.81 (2H, each as d, J ) 9.7 Hz), 4.15 (1H, d, J
) 1.4 Hz), 4.72 (1H, dd, J ) 2.4 and 1.4 Hz), 5.72 (1H, br), 5.80
(1H, d, J ) 2.4 Hz), 8.07 (1H, s), 8.55 (1H, br), 8.77 (1H, s); 13C
1102 J. Org. Chem., Vol. 71, No. 3, 2006